Background-Abciximab reduces major adverse cardiac events in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention (PCI 
I
n patients with acute ST-elevation myocardial infarction, primary percutaneous coronary intervention (PCI) is the preferred reperfusion regimen if performed by experienced operators in a timely manner. 1 Nevertheless, myocardial damage is not immediately terminated after successful epicardial reperfusion by primary PCI. Current strategies are directed at improving myocardial tissue perfusion, which is impaired in Ϸ50% of patients and has prognostic impact. 2, 3 Adjunctive abciximab administration is an established therapy to improve coronary microcirculation and reduces major cardiac adverse events. 4 -9 Intravenous abciximab administration has been studied in randomized clinical trials. 6 Intracoronary abciximab bolus administration with very high local platelet inhibitor concentrations may be favorable in dissolution of thrombi and microemboli with subsequent improved myocardial microcircula-tion and reduced no reflow and infarct size. 10, 11 Currently, clinical experience in the efficacy of intracoronary abciximab administration is limited. [12] [13] [14] [15] [16] 
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Therefore, the aim of this randomized trial was to assess the effects of intracoronary versus intravenous abciximab bolus administration on the occurrence of no reflow and infarct size assessed by contrast-enhancement magnetic resonance imaging.
Methods Patients
From February through November 2006, we randomly assigned in an open-label fashion 154 consecutive patients with ST-elevation myocardial infarction undergoing primary PCI to either intracoronary or intravenous bolus abciximab (0.25 mg/kg body weight) administration with subsequent 12-hour intravenous infusion at a dose of 0.125 g/kg per minute (maximum, 10 g/min). Balanced randomization was performed by drawing sealed unlabeled envelopes placed in no order in an urn. Inclusion criteria were the presence of symptoms Ͻ12 hours and ST-segment elevation of at least 0.1 mV in Ն2 extremity leads or at least 0.2 mV in Ն2 precordial leads. Exclusion criteria were prior fibrinolysis; known allergy to heparin, aspirin, or abciximab; active severe bleeding; pregnancy; history of major surgery Ͻ4 weeks; and cardiogenic shock with mechanical ventilation. Furthermore, patients with contraindications to magnetic resonance imaging at study entry such as implanted pacemakers, defibrillators, or metallic intracranial implants were excluded. The study was approved by the local ethics committee, and all patients gave written informed consent.
Study Protocol
Per protocol, the abciximab bolus administration should be performed before PCI. In the intracoronary group, bolus administration was recommended after infarct-related artery recanalization by the PCI wire before balloon dilatation to allow high abciximab concentration in the target region. The bolus was administered directly within 1 minute through the PCI guiding catheter. Filtering was performed before the abciximab solution was pulled into the syringe. In cases with extreme short door-to-balloon times, abciximab bolus administration was allowed to be performed after PCI because of the predominant importance of timely optimized reperfusion. All patients received 500 mg aspirin and heparin (60 U/kg body weight) intravenously before PCI. Stenting of the culprit lesion was recommended unless the vessel had a diameter Ͻ2.0 mm. Clopidogrel (600 mg orally during PCI, if not administered before, followed by 75 mg/d for at least 9 months) was mandatory. A clopidogrel loading dose Ͼ1 hour before PCI was administered in Ͻ10% of the patients. Aspirin was given indefinitely at a dose of 100 mg/d. The sheath was removed after PCI, and the puncture site was closed by a closure device (AngioSeal, Boston Scientific, Boston, Mass) or by 12-hour gradual compression with a compression system (FemoStop II Plus, RADI Medical Systems, Uppsala, Sweden). Heparin was paused for 4 hours after PCI and subsequently infused for a minimum of 12 hours with the dose adjusted to achieve an activated partial thromboplastin time between 50 and 70 seconds.
Angiographic Analysis
Coronary angiography of the target lesion was performed before and after PCI with the same projections. Angiographic projections used were those that allowed optimal evaluation of the Thrombolysis in Myocardial Infarction (TIMI) flow and TIMI perfusion grades of the infarct-related artery or the myocardium supplied by it. 17, 18 Angiographic analysis included initial and final flow and perfusion of the culprit vessel, as defined previously. 17, 18 Visual assessments were performed offline in the angiographic core laboratory by 2 blinded observers (G.F. and I.E.).
ST-Segment Resolution
For ECG interpretation, blinded observers (J.F. and I.E) measured the sum of ST-segment elevation 20 ms after the end of the QRS complex in the ECG before and that obtained early after PCI after transfer to the intensive care unit. ST-segment resolution was calculated as the sum of ST elevation before minus the sum of ST elevation after PCI divided by the sum of ST elevation before PCI. ST-segment resolution was expressed as a percentage. 19 
Infarct Size Measured by Enzyme Release
The infarct size was measured indirectly by the area under the curve of the creatine kinase release derived from measurements every 6 hours over 2 days.
Magnetic Resonance Imaging
Myocardial infarct size and microvascular obstruction were determined by magnetic resonance imaging at day 1 to 4 after the index event. Imaging was performed on a 1.5-T scanner (Philips Intera CV, Best, the Netherlands). Left ventricular function was assessed by a standard steady-state free precession technique. 20 For acute infarct determination, 3 short-axis slices using a T2-weighted turbo spinecho sequence were obtained. 21, 22 Early and delayed enhancement images covering the whole ventricle were acquired Ϸ1 and 15 minutes after intravenous administration of 0.15 mmol/kg body weight gadobutrol (Gadovist, Schering, Germany) with an inversion recovery gradient echo sequence. 23 The inversion time was adapted individually to null normal myocardium. All measurements were performed by fully blinded operators (K.S. and H.T.) at the magnetic resonance core laboratory, which has excellent intraobserver and interobserver variabilities and excellent reproducibility for infarct size measurement. 24 Left ventricular ejection fraction and end-diastolic and end-systolic volumes were calculated from the short-axis views. Total left ventricular myocardial mass and infarct size, expressed as a percentage of left ventricular mass, were assessed manually as described previously. 24 Extent of microvascular obstruction in early and delayed images was determined similarly by manual drawing of the obstructed area within the infarction of the short-axis slices and expressed as a percentage of the left ventricular mass.
End Points
The primary end point was final infarct size and microvascular obstruction extent assessed by contrast-enhanced magnetic resonance imaging. Secondary end points were early ST-segment resolution as an indirect parameter of myocardial tissue perfusion, the angiographic TIMI flow and perfusion grades after PCI, 17, 18 and infarct size measured by the area under the curve of creatine kinase release. The clinical secondary end point was a composite of major adverse cardiovascular events defined as a composite of death, reinfarction, urgent target vessel revascularization, and occurrence of new congestive heart failure within 30 days after randomization. Posthospital follow-up included 1 outpatient visit at 30 days. The diagnosis of reinfarction was based on clinical symptoms, new ST-segment changes, and an increase in the creatine kinase and MB levels above the reference limits in patients with normalized values after the index event or if there was an increase of at least 50% from the last nonnormalized measurement. New heart failure was defined as any congestive heart failure (rales, dyspnea New York Heart Association class III to IV) occurring Ͼ24 hours after the index event. Outcomes were adjudicated by clinical events committee members (G.S., E.G., and H.T.) who were unaware of the patient's assigned treatment.
Statistical Analysis
The number of patients included in this study was based on the primary end point of infarct size and extent of microvascular obstruction. From previous trials and a pilot trial, we projected a final infarct size of 20Ϯ10% (5Ϯ4% microvascular obstruction) after intravenous abciximab administration. 24 -27 With a power of 80% and a 2-sided ␣ value of 0.05, we estimated that 68 patients would be required in each group to detect an absolute difference of 5% in infarct size (2% microvascular obstruction). A total of 154 patients were included to allow for the possibility of missing magnetic resonance imaging studies. Predefined subgroup analysis was performed for anterior/nonanterior infarction, postprocedural angiographic flow and perfusion grades 3 versus Ͻ3, and different times from symptom onset to reperfusion (Ͻ4 versus 4 to 12 hours). Each categorical variable is expressed as a number and percentage of patients. Continuous parameters were estimated as median with interquartile range. Differences between treatment groups were assessed by Fisher's exact or the 2 test for categorical variables and by the Student t test for continuous data with normal distribution. Otherwise, the nonparametric Wilcoxon rank-sum test was used. For the combined secondary clinical end point, the Kaplan-Meier method was applied, and differences were assessed by the log-rank test. All statistical tests were performed with SPSS software version 14.0 (SPSS Inc, Chicago, Ill). A 2-tailed value of PϽ0.05 was considered statistically significant.
The authors had full access to and take responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Of the 154 patients enrolled, 77 were randomly assigned to intracoronary and 77 to intravenous abciximab administration ( Figure 1) . This was an all-comers study, and no eligible patients were excluded during the study period. All patients received the assigned treatment. The baseline characteristics and medication were similar between groups (Table 1) . Abciximab bolus administration was performed in all patients. Before PCI, it was accomplished in 83% in the intracoronary and 77% in the intravenous group (Pϭ0.42). Discontinuation of glycoprotein IIb/IIIa inhibitor administration was necessary in 4 (nϭ2 groin bleeding, nϭ1 hematemesis, nϭ1 pericardial effusion) intracoronary and 5 (nϭ3 groin bleeding, nϭ1 pericardial effusion, nϭ1 diffuse bleeding caused by thrombocytopenia) intravenous group patients (Pϭ0.93). There were no adverse events during intracoronary abciximab bolus administration. Reperfusion times were similar with a median time from symptom onset to PCI of 244 minutes (interquartile range, 163 to 433 minutes) and 218 minutes (interquartile range, 159 to 323 minutes; Pϭ0.47), respectively. Thirty-seven (49%) and 46 (60%) patients were treated within the first 4 hours after symptom onset (Pϭ0.20). The door-to-balloon time was 31 minutes (interquartile range, 22 to 40 minutes) versus 29 minutes (interquartile range, 21 to 40 minutes; Pϭ0.77).
Infarct Size and Microvascular Obstruction
Results of magnetic resonance imaging were available in 67 (87%) of the intracoronary and in 71 (92%) of the intravenous abciximab group patients (Figure 1 ). The median time between randomization and magnetic resonance imaging was 2 days (interquartile range, 2 to 3 days) for both groups (Pϭ0.94). The primary end point of infarct size was significantly smaller after intracoronary compared with intravenous abciximab bolus administration. Similarly, the extent of microvascular obstruction was smaller in the intracoronary 
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than the intravenous group at early and late imaging (Table  2) . However, left ventricular ejection fraction and enddiastolic and end-systolic volume indexes were similar between both groups at this early stage after the index event ( Table 2) . The primary end points of infarct size and microvascular obstruction also were analyzed in several predefined subgroups. Patients with anterior infarction had greater benefit from intracoronary versus intravenous abciximab bolus administration with respect to infarct size (16 Pϭ0.03) microvascular obstruction. There also was a greater benefit for intracoronary abciximab infusion in patients with impaired TIMI flow and perfusion grades after PCI. These results are given in Figure 2a and 2b.
Enzymatic Infarct Size
The enzymatic infarct size assessed by the area under the curve of creatine kinase release was smaller in the intracoronary group with 575 mol · L Ϫ1 · h Ϫ1 (interquartile range, 359 to 863 mol · L Ϫ1 · h Ϫ1 ) compared with the intravenous abciximab group with 736 mol · L Ϫ1 · h Ϫ1 (interquartile Figure 3 ).
ST-Segment Resolution
In 2 intracoronary abciximab patients, the ST-segment resolution was not interpretable because these patients required pacing as a result of atrioventricular block grade 3 
Angiographic Analysis
The TIMI flow and TIMI perfusion grades before PCI were similar (Table 3) . After PCI, the majority of patients had a TIMI grade 3 flow (84.4% versus 85.7%, respectively). In the intracoronary abciximab group, there was a trend toward improved TIMI perfusion grade after PCI (Pϭ0.09; Table 3 ).
Clinical Outcome
At the 30-day follow-up, there were 2 cardiac deaths (2.6%) in the intracoronary and 3 (3.9%) in the intravenous abciximab group. Nonfatal reinfarctions occurred in 0 subjects after intracoronary and in 2 (2.6%) after intravenous abciximab application. The need for target vessel revascularization was identical (0 versus 2 [2.6%]). New congestive heart failure occurred in 2 (2.6%) and 5 (6.5%) patients, respectively. Thus, the composite major adverse cardiac event rate at the 30-day follow-up was 5.2% after intracoronary and 15.6% after intravenous abciximab administration (relative risk, 0.33; 95% CI, 0.09 to 1.05; Pϭ0.06; Figure 4 ).
Discussion
This first adequately powered randomized clinical trial of intracoronary versus intravenous abciximab administration in patients undergoing primary PCI for ST-elevation myocardial infarction showed a reduction in microvascular obstruction extent and infarct size as assessed by magnetic resonance imaging, which is a state-of-the-art imaging technique. Furthermore, myocardial tissue perfusion assessed by STsegment resolution was significantly better after intracoronary abciximab bolus administration. This resulted in a trend toward better clinical outcome with respect to a combined clinical end point. However, in the acute setting after the index event, there was no improvement in left ventricular function and volumes. These beneficial effects of intracoronary abciximab administration might be explained by the high local doses, which may facilitate the diffusion of the antibody to platelets inside the flow-limiting thrombus, thus resulting in improved dissolution of thrombi and microemboli at the ruptured plaque and further downstream in the microcirculation. Therefore, by protocol, the bolus administration was recommended after thrombus penetration by the PCI guidewire to achieve very high local concentration. This could not be accomplished in all patients as a result of the very short door-to-balloon times when preparation of the abciximab bolus took longer than PCI. The higher local concentration effects are supported by the larger effects on infarct size and microvascular obstruction in patients with postinterventional impaired flow and perfusion. Depending on the relation of inflow and outflow and the size of the ischemic area, the local abciximab concentration can vary substantially. However, even in situations with restitution of normal flow and perfusion in the infarct-related artery, intracoronary abciximab bolus administration will result in very high local concentrations, which might be much higher than the usual intravenous application mode that reduces platelet aggregation to Ͻ20% within 10 minutes. 28 Another potential mechanism of high local concentrations might be related to the antiinflammatory properties of abciximab. 7 These clinical considerations are supported by experimental data showing a dose-dependent platelet disaggregation. Concentrations that produced complete platelet disaggregation also induced partial displacement of platelet-bound fibrinogen, which might play a role in the clinical setting. 29 Previous trials assessing the effect of intracoronary abciximab administration were limited to case reports, retrospective registries, and small randomized trials. [12] [13] [14] [15] [16] In one of these trials, angiographic reperfusion was improved in the intracoronary abciximab group as assessed by the corrected TIMI frame count. Furthermore, there was a trend toward lower infarct size as assessed by cardiac enzymes. 15 In a small randomized clinical trial of 45 patients, there was a significantly higher degree of myocardial salvage with subsequent lower infarct size as assessed by serial scintigraphy. In another randomized trial of 137 patients, lower troponin I levels after PCI were observed. There was no improved clinical outcome, which might be due to the low-risk patient subgroup; Ͻ50% had ST-segment elevation. The present results with regard to infarct size and microvascular obstruction might explain the improved clinical outcome after intracoronary abciximab administration that was evident in the present trial and 2 previous retrospective registries of 403 and 173 patients. 14, 16 An important factor is timing of glycoprotein IIb/IIIa inhibitor administration. Clinical trials have shown that earlier administration results in higher preinterventional TIMI flow with subsequent improved perfusion after PCI. 30, 31 However, in a pooled analysis and a recently published trial, there was no effect on mortality or clinical end points. 32, 33 Because the door-to-balloon-times were extremely short in a highly experienced tertiary care center in the present trial, earlier abciximab administration requires treatment in the prehospital setting, which poses substantial logistical obstacles. Early complete ST-segment resolution Ͼ70% was observed in 50% to 59% in the early-administration-treated patients, which is comparable to the intravenous group in our trial but lower than in the intracoronary group. 30, 31 Similarly, the angiographic perfusion grade after PCI was similar between the intravenous group and previously published results, whereas the intracoronary group had nonstatistically significant higher perfusion grades. 31 Infarct size as an end point in reperfusion trials has been advocated because of its potential prognostic value. 34 We used a sensitive and reliable method, which, compared with scintigraphic studies, has the advantage of higher spatial resolution with the ability to detect even small subendocardial infarcts and allows a sample size reduction because of its accuracy. 24, 35, 36 In addition, magnetic resonance imaging allows assessment of microvascular obstruction, which has prognostic impact. 37, 38 Currently, there is no consensus on the best imaging technique for assessment of microvascular obstruction. 37, 38 As a consequence, we measured microvascular obstruction at 2 different time points, which revealed a previously described reduction in microvascular obstruction over time. 38 From a theoretical point of view, magnetic resonance can be used for measurement of myocardial salvage but has not yet been applied in humans. 22 Therefore, we used only 3 short-axis slices of T2-weighted images for the delineation of chronic and acute myocardial infarction in patients with previous infarction. 21, 22 Mechanisms underlying impaired myocardial perfusion after restoration of epicardial blood flow are likely to be multifactorial such as oxygen free radicals, cellular and interstitial edema, endothelial dysfunction, vasoconstriction, and thromboembolism. 2, 39 The secondary angiographic and electrocardiographic end points are well established for the assessment of perfusion at the epicardial and microvascular levels. However, the TIMI flow and perfusion grades might . Kaplan-Meier curve of the cumulative incidence of death, reinfarction, new congestive heart failure, or target vessel revascularization during the first 30 days after randomization. The log-rank test was used to calculate the probability value.
be too insensitive to detect differences in the very early setting after abciximab bolus administration. 17, 18 In contrast, the sensitive ECG assessment at a later measurement reflected improved tissue perfusion. 19 A limitation is that this trial had sufficient statistical power only to assess final infarct size and extent of microvascular obstruction. Confirmation of the results with respect to clarification of the long-term effects on ventricular size and function and, more important, on clinical outcome requires a larger trial. Although all angiographic, ECG, and magnetic resonance imaging measurements were blinded, patients and interventionalists were aware of the group assignment. Thus, a potential investigator bias cannot be ruled out entirely. Some patients had to be excluded from magnetic resonance infarct size assessment. Because the number of patients in both groups was identical and the baseline characteristics of patients undergoing and those not undergoing magnetic resonance imaging were similar, a potential selection bias is limited.
Conclusions
Intracoronary bolus administration of abciximab is superior to standard intravenous treatment with respect to reduction in infarct size, extent of microvascular obstruction, and improvement of perfusion in primary PCI. An adequately powered trial for clarification of this approach on the longterm benefit on ventricular function, ventricular volumes, and major adverse cardiac event reduction is warranted.
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